Table 1.
Opportunities highlighted by the working party1
| Specialty | Area of further research/opportunities |
|---|---|
| Allergy | Immediate- and delayed-type hypersensitivity reactions |
| Anaesthesia | Exploration of any genetic component to ‘accidental awareness’ during anaesthesia |
| Cardiology | Wider subspecialty integration of pharmacogenomics |
| Diabetes and endocrinology | Monogenic diabetes therapy / variability in response to metformin / agranulocytosis in response to thyroid-supressing medications / adrenal suppression in response to corticosteroids |
| Gastroenterology and hepatology | Upper gastrointestinal ulceration / therapies for inflammatory bowel disease / drug-induced liver injury |
| Haematology | Phenotypic vs genotypic testing |
| Infectious diseases | Antibiotics and antivirals: dosing and adverse effects |
| Neurology | Personalised approach to anti-epileptic therapy / multiple sclerosis therapies |
| Obstetrics and gynaecology | Fertility treatments / teratogenicity |
| Oncology | Efficacy of dose-reduced therapeutics in response to pharmacogenomic testing and evidence to guide dose reduction and escalation |
| Ophthalmology | Steroid-induced glaucoma / treatments for macular degeneration |
| Paediatrics | International consortium to enable research in pharmacogenomics in children |
| Pharmacy | Role of pharmacists in all settings, and community pharmacies in implementation of pharmacogenomics |
| Primary care | Implementation of pharmacogenomics into primary care, decision support systems |
| Psychiatry | Optimising antidepressant therapy / identifying those at highest risk of adverse effects from antidepressant and antipsychotic therapies |
| Renal | Immunosuppressants in renal disease and renal transplantation / antihypertensives / antibiotics |
| Respiratory | Asthma treatment optimisation / targeted pulmonary fibrosis and cystic fibrosis therapeutics |
| Rheumatology | Osteonecrosis of the jaw in response to bisphosphonates / immunosuppressants and biologics |